ChemicalBook >> journal list >> MedComm >>article

MedComm

IF: 10.7
Download PDF

Outer membrane vesicle contributes to the Pseudomonas aeruginosa resistance to antimicrobial peptides in the acidic airway of bronchiectasis patients

Published:30 January 2025 DOI: 10.1002/mco2.70084 PMID: 39896756
Yingzhou Xie, Yi-Han Shi, Le-Le Wang, Cheng-Wei Li, Min Wu, Jin-Fu Xu

Abstract

Pseudomonas aeruginosa is the predominant pathogen causing chronic infection in the airway of patients with bronchiectasis (BE), a chronic respiratory disease with high prevalence worldwide. Environmental factors are vital for bacterial successful colonization. Here, with sputa and bronchoalveolar lavage fluids, we determined that the concentration of airway antimicrobial peptide LL-37 and lactate was elevated in BE patients, especially in those infected with P. aeruginosa. The in vitro antibacterial assay revealed the bactericidal activity of LL-37 against the clinical P. aeruginosa isolates, which were dampened in the acidic condition. P. aeruginosa production of outer membrane vesicles (OMVs) enhanced in the lactate-adjusted acidic condition. Transcriptomic analysis suggested that OMVs induce the hyperproduction of the chemical compound 2-heptyl-4-quinolone (HHQ) in the bacterial population, which was verified by high-performance liquid chromatography. The positively charged HHQ interfered with the binding of LL-37 to bacterial cell membrane, potentiating the P. aeruginosa resistance to LL-37. To our knowledge, this is a new resistance mechanism of P. aeruginosa against antimicrobial peptides and may provide theoretical support for the development of new antibacterial therapies.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
2-HEPTYL-3-HYDROXY-4-QUINOLONE 108985-27-9 C16H21NO2 71 suppliers $65.00-$2350.12
2-HEPTYL-3-HYDROXY-4-QUINOLONE 108985-27-9 C16H21NO2 71 suppliers $65.00-$2350.12
2-Heptylquinoline-4(1H)-one 40522-46-1 C16H21NO 43 suppliers $72.39-$924.00
2-Heptylquinoline-4(1H)-one 40522-46-1 C16H21NO 43 suppliers $72.39-$924.00

Similar articles

IF:0

Resistance to trimethoprim-sulfamethoxazole.

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America G. Eliopoulos, P. Huovinen,etc Published: 1 June 2001
IF:10.5

Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure

JAMA Network Open Katherine L. Modzelewski, Alexandra Pipilas,etc Published: 2 May 2024